PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

AXS-05 Shows Antidepressant Separation From Control by Week 1 in MDD

dextromethorphan-bupropionAXS-05NMDA receptor antagonistsigma-1 agonistmajor depressive disorderrandomized controlled trialMADRSrapid onset antidepressantpsychopharmacology Psychiatry / Psychopharmacology

Background Information

Can an investigational NMDA antagonist deliver rapid relief in depression?

AXS-05 is a novel treatment option for major depressive disorder (MDD) that shows rapid antidepressant effects. AXS-05 showed significant improvements over placebo and bupropion in depression symptoms as early as Week 1, with notable improvement in Montgomery-Åsberg Depression Rating Scale scores. While promising, AXS-05 is still investigational, and the study outcomes need to be validated across larger populations before influencing routine clinical practice. AXS-05 demonstrates rapid antidepressant effects, but further validation is necessary before clinical use.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Jones A, Streicher C, Alter S, Thomas Z, Tabuteau H

Citation: Jones A, Streicher C, Alter S, et al. Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist in Major Depressive Disorder: Results From Two Randomized Double-Blind, Controlled Trials. CNS spectrums. 2023;28(2):263. doi:10.1017/S1092852923002158

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.